rp-2

Rp-2'-Deoxyuridine-5'-O-(1-thiotriphosphate) (Rp-dUTP-α-S), a sulfur-containing nucleotide isomer and purinergic P2Y2 receptor agonist, preferentially promotes inositol phosphate accumulation in 1321N1 astrocytoma cells with P2Y2 receptors (EC50 = 12.5 µM) compared to those expressing P2Y4 receptors at a concentration of 10 µM.

Rp-2'-O-Me-CTPαS is an analog of CTP featuring a modified 2'-OH group.

Rp-2'-O-Me-GTPαS tetrasodium is a GTP analog with a modified 2'-OH group.

Rp-2'-Deoxy-2'-fluoroadenosine-5'-O-(1-thiotriphosphate) (sodium) is an isomer of the sulfur-containing nucleotide derivative 2’-F-dATP-α-S.

Rp-2'-Deoxyadenosine-5'-O-(1-thiodiphosphate) (Rp-dADP-α-S) sodium is an isomer of Sp-2'-Deoxyadenosine-5'-O-(1-thiodiphosphate) sodium.

PARP-2-IN-3 is used as a potent PARP-2 inhibitor (IC50=0.07 μM) with anti-tumor activity that induces apoptosis and necrosis in cancer cells, and can be used for the study of breast cancer.128-52-56-8

PARP-2-IN-1 is a potent and selective inhibitor of PARP-2 (IC50 of 11.5 nM).

RP-23618 is a non-peptidic antagonist of RANTES.

KRP297 is a PPAR agonist potentially for the treatment of type 2 diabetes and dyslipidemia.

Tyrosinase-related Protein 2 (TRP-2) (181-188) is a peptide derived from TRP-2, specifically corresponding to residues 180-188, and it is the primary epitope within TRP-2 recognized by anti-B16 CTLs. Additionally, it conforms to the binding motif of the MHC class I H2-Kb.

BRP-201 is a selective, novel, and potent inhibitor of mPGES-1 (IC50: 0.42 μM) and is considered a promising therapeutic target for the next generation of anti-inflammatory drugs for the treatment of inflammatory diseases.

PARP-2/1-IN-2, an enantiomer of Veliparib, serves as a potent inhibitor of PARP, demonstrating inhibition constants (Kis) of 2 nM for PARP-2 and 5 nM for PARP-1. This compound exhibits a half-maximal effective concentration (EC50) of 3 nM in cell-based assays evaluating PARP activity [1].

This peptide is a TRP-tyrosinase-related protein. Its immunization results in effective induction of antitumor immunity.

RP-220 is a peptide that targets the NLRP3 enzyme and exhibits anti-inflammatory and anti-apoptotic properties. It inhibits apoptosis of renal tubular epithelial cells caused by alkaline damage by activating the MAPK signaling pathway. In mouse models of acute kidney injury (AKI), RP-220 significantly reduces NLRP3 expression, macrophage infiltration, and renal tissue damage. Additionally, RP-220 is applicable in research on systemic lupus erythematosus (SLE) and its complication lupus nephritis (LN).

Olaparib (KU0059436) is a small molecule inhibitor of PARP1/PARP2 (IC50=5/1 nM), with weak inhibitory activity against PARP tankyrase-1 (IC50=1.5 μM), and is selective and orally active. Olaparib exhibits autophagy and mitochondrial autophagy activation activity.

Cytochalasin D is an actin inhibitor, the removal of actin stress fibers is crucial for the chondrogenic differentiation. It may be an inhibitor of some fertilization processes such as sperm penetration or sperm head decondensation. Cytochalasin D inhibit

Talazoparib (LT-673) is a new-type PARP inhibitor (IC50: 0.58 nM), It similarly binds to PARP1/2 (Kis: 1.2/0.85 nM).

RBN-3143 is a potent inhibitor of NAD+-competitive catalytic PARP14 (IC50= 4 nM), which inhibits ADP-ribosylation mediated by PARP14 and stabilizes PARP14 in cell lines, demonstrating research potential for lung inflammation.

Niraparib, also know as MK-4827, is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. MK4827 inhibits PARP activity, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. The PARP family of proteins detect and repair single strand DNA breaks by the base-excision repair (BER) pathway.

JNJ-54175446 (JNJ-5446) is a CNS-permeable and selective P2X7 receptor antagonist that attenuates the release of IL-1β/IL-18 from microglia, and may be used in the study of depression.

N-5984, a β3-adrenergic receptor agonist, is used potentially for the treatment of obesity, overactive bladder and type 2 diabetes.

BRK inhibitor P21d hydrochloride is a highly potent inhibitor of breast tumor kinase (BRK/PTK6), displaying an IC50 of 30 nM, and effectively suppresses p-SAM68 with an IC50 of 52 nM. This compound serves as a valuable tool for evaluating BRK inhibitors' efficacy in xenograft breast tumor models, enabling in vivo activity assessment.

CEP-9722 is an orally active, selective and potent inhibitor of poly (ADP-ribose) polymerase-1 PARP-1 and poly (ADP-ribose) polymerase-12 PARP-2, with anticancer activity, and can be used for the study of ovarian cancer.

PARP1/2/TNKS1/2-IN-1 is a multi-target inhibitor of PARP-1, PARP-2, TNKS1, and TNKS2, with potential anti-tumor activity that induces apoptosis.